Abstract
BackgroundThe purpose of this study is to assess the role of 18 fluorodeoxyglucose positron emission tomography/computed tomography (18FDG PET-CT) in the follow-up of patients with lymphoma after finishing therapy.ResultsThis study included 42 lymphomas (25 non-Hodgkin’s lymphoma and 17 Hodgkin’s lymphoma); patients ranging in age from 18 to 70 years were examined by 18FDG PET-CT after therapy and analyzed retrospectively. Confirmatory biopsy was mandatory in cases of suspected disease recurrence and follow-up in cases of complete metabolic response. Positron emission tomography/computed tomography in assessment of lymphoma treatment response reveals significant statistical significance (P < 0.05). It shows 100% sensitivity, 92.8% specificity, and 95.2% accuracy in the prediction of response.ConclusionPositron emission tomography/computed tomography plays an important role in detection of response to treatment of lymphoma after finishing therapy.
Highlights
The purpose of this study is to assess the role of 18 fluorodeoxyglucose positron emission tomography/computed tomography (18FDG Positron emission tomography–computed tomography (PET-CT)) in the follow-up of patients with lymphoma after finishing therapy
This review provides an overview of the updated PET-CT response criteria to familiarize the radiologist with the most important and clinically relevant aspects of lymphoma imaging [15, 16]
Positron emission tomography (PET) using 18 FFDG integrated with computed tomography (CT) (PET/CT) has become widely used in the diagnosing, staging, and evaluation of therapy response in lymphomas [19]
Summary
The purpose of this study is to assess the role of 18 fluorodeoxyglucose positron emission tomography/computed tomography (18FDG PET-CT) in the follow-up of patients with lymphoma after finishing therapy. Fluorodeoxyglucose positron emission tomography/ computerized tomography (18FDG PET/CT) [1] is a powerful imaging modality in the field of oncology since it detects the enhanced glycometabolic activity of neoplastic cells, with the ability to define tumor burden and involved organs. Analyzing 18FDG PET positivity patterns during follow-up to distinguish patients who should be referred to an immediate surgical biopsy to start further treatment from patients who could be managed with a more conservative observational approach that could be repeating imaging after 2 or 3 months to confirm or avoid biopsy [2, 4]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
